Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.36 Analyst target: $10.19 Upside: 331.78%
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and neuromuscular diseases. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.